BiomX (PHGE) Notes Payables (2018 - 2026)

BiomX (PHGE) posted Notes Payables of $1.3 million for Q1 2026, up 234.4% sequentially from $375000.0 in Q4 2019.

BiomX (PHGE) Notes Payables (2018 - 2026) Analysis & Trends

BiomX has reported Notes Payables for 3 years, with the latest figure at $1.3 million in Q1 2026.

Quarterly Notes Payables changed N/A year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (changed N/A YoY) and the FY2019 annual result came in at $375000.0, changed N/A from the prior year.
Notes Payables rose to $1.3 million in Q1 2026 per PHGE's latest filing, from $375000.0 in the prior quarter.
Over five years, Notes Payables peaked at $1.3 million in Q1 2026 and troughed at $1.3 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	BiomX	361,408.40	-806,591.60	-

Download Data